- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Magrolimab, Pembrolizumab, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Chandler, Arizona • Duarte, California • Los Angeles, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1513–1536
of 1,852
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer
- Interventions
- Evorpacept (ALX148), Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Aurora, Colorado • New Brunswick, New Jersey + 1 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, Boserolimab, MK-4830, diphenhydramine, acetaminophen, MK-0482
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
- Conditions
- Advanced Solid Tumours
- Interventions
- EBC-129, Pembrolizumab
- Drug
- Lead sponsor
- EDDC (Experimental Drug Development Centre), A*STAR Research Entities
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Houston, Texas
- Conditions
- Non Small Cell Lung Cancer Metastatic
- Interventions
- Acasunlimab, Pembrolizumab
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more
- Conditions
- Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab
- Drug · Radiation · Other + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
- Interventions
- Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Intima Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Minneapolis, Minnesota
- Conditions
- Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors
- Interventions
- Pembrolizumab, Enfortumab vedotin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-small Cell Lung Cancer, NSCLC
- Interventions
- Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
- Conditions
- Glioma, Recurrent Malignant Glioma
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
- Conditions
- HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil, Capecitabine, Cisplatin, Oxaliplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 58
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 51 more
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma
- Interventions
- Telatinib, Keytruda
- Drug
- Lead sponsor
- Andrew Hendifar, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Los Angeles, California
- Conditions
- Non Small Cell Lung Cancer, Metastasis, Recurrence
- Interventions
- Pembrolizumab, Idelalisib
- Drug
- Lead sponsor
- Asha Nayak
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
- Interventions
- EIK1001, Pembrolizumab (KEYTRUDA®), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, Pemetrexed + Cisplatin /Carboplatin
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 18
- States / cities
- Daphne, Alabama • Glendale, California • Orange, California + 15 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Interventions
- Pembrolizumab, Talabostat Mesylate
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neoplasms, Colorectal Cancer
- Interventions
- MK-8353, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Grand Rapids, Michigan • Nashville, Tennessee
- Conditions
- High Grade Glioma
- Interventions
- Pembrolizumab, Pemetrexed, Abemaciclib
- Drug
- Lead sponsor
- Jose Carrillo
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
- Interventions
- Pembrolizumab, 177Lu-PSMA-617
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- Predictive models (data collection)
- Other
- Lead sponsor
- Sophia Genetics SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Iowa City, Iowa • Worcester, Massachusetts • Rochester, Minnesota + 3 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 28
- States / cities
- Fresno, California • Glendale, California • Orange, California + 22 more
- Conditions
- Merkel Cell Carcinoma, Small Cell Lung Cancer
- Interventions
- XmAb18087, XmAb18087 ± Pembrolizumab
- Biological · Drug
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Duarte, California • Los Angeles, California • Lebanon, New Hampshire + 3 more
- Conditions
- Triple Negative Breast Cancer, Breast Cancer
- Interventions
- Trilaciclib, Cylophosphamide, Doxorubicin, Paclitaxel, Carboplatin (Investigator discretion), Pembrolizumab (Investigator discretion)
- Drug · Biological
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Los Alamitos, California • Santa Monica, California • Whittier, California + 4 more
- Conditions
- Carcinoma, Non-small Cell Lung
- Interventions
- Abemaciclib, Pemetrexed, Gemcitabine, Ramucirumab, LY3023414, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 8
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Sacramento, California + 5 more
- Conditions
- Glioblastoma
- Interventions
- Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery
- Drug · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland